Dokoh S, Fukunaga M, Yamamoto I, Torizuka K, Morita R
Department of Radiology, Kyoto City Hospital, Japan.
Radioisotopes. 1988 Jun;37(6):339-42. doi: 10.3769/radioisotopes.37.6_339.
Bone scintigraphy using 99mTc-MDP was performed on 2 patients with Paget's disease of bone before and after the treatment with a synthetic eel calcitonin analogue [Asu1,7)-eel calcitonin, ECT] at a dose of 40 U per day. All pagetic lesions showed markedly the increased accumulation of the radionuclide. The uptake ratio, defined as the count rate of 99mTc-MDP over each bone lesion to that over the control bone, was calculated. The response to the calcitonin therapy was evaluated with the uptake ratio of the radionuclide. The uptake ratio decreased markedly within the first 3 months of the treatment, in association with a palliation of bone pain, while the serum alkaline phosphatase activities which had been within the normal range or slightly high before the treatment did not show any significant change or did not reflect a clinical feature (e.g. bone pain) with the treatment. Thus, the uptake ratio on the bone scintigram seemed to offer the most sensitive and most reliable information for the evaluation of calcitonin treatment of Paget's disease of bone.
对2例骨Paget病患者在使用合成鳗鱼降钙素类似物[（1-7位为精氨酸）鳗鱼降钙素，ECT]治疗前后，均采用99mTc-MDP进行骨闪烁显像，剂量为每日40U。所有骨病变部位均显著显示放射性核素摄取增加。计算摄取率，摄取率定义为每个骨病变部位99mTc-MDP的计数率与对照骨的计数率之比。用放射性核素摄取率评估降钙素治疗的反应。在治疗的前3个月内摄取率显著下降，同时骨痛缓解，而治疗前在正常范围内或略高的血清碱性磷酸酶活性未显示任何显著变化，或未反映治疗的临床特征（如骨痛）。因此，骨闪烁显像上的摄取率似乎为评估骨Paget病的降钙素治疗提供了最敏感和最可靠的信息。
